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Aim: Stress has been implicated in the pathogenesis of 
Hashimoto's thyroiditis (HT), nevertheless evidence is 
scarce regarding the effect of stress management on 
individuals suffering from HT. The purpose of this 
study was to evaluate the impact of an 8-week stress 
management intervention on the anti-thyroid peroxi-
dase (anti-TPO) and anti-thyroglobulin (anti-TG) anti-
bodies as well as thyroid-stimulating hormone (TSH) 
levels of women with HT. Secondary endpoints in-
cluded the effect on the patients’ lifestyle, body mass 
index (BMI), depression, anxiety and stress. Methods: 
This was a two-arm parallel group (stress management 
intervention vs. standard care groups) randomized con-
trolled study. Adult women with Hashimoto's thyroidi-
tis, completed questionnaires on stress, anxiety, de-
pression and lifestyle, at the beginning of the pro-
gramme and 8 weeks later. Laboratory thyroid func-
tion tests (anti-TPO, anti-TG antibodies and TSH) 
were also measured at baseline and at the end of the 
study. Results: A total of 60 women with HT, aged 25
-76 years, participated in the study (30 patients in each 
group). After eight weeks, patients in the intervention 
group demonstrated statistically significant beneficial 
decrements in the rate change of anti-TG titers and the 
levels of stress, depression and anxiety as well as bet-
ter lifestyle scores, compared to the control group.  
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Introduction 
 
Autoimmune thyroiditis affects a large percentage of 
the population worldwide and is attributed to a 
combination of genetic and environmental factors 
(Wasserman et al. 2009). Hashimoto’s thyroiditis 
(HT), the most common type of autoimmune 
thyroiditis, is characterized by the detection of 
antithyroid antibodies i.e. anti-thyroid peroxidase (anti
-TPO) and anti-thyroglobulin (anti-TG) antibodies 
with or without symptoms of hypothyroidism (e.g. 
weight gain, fatigue, cold intolerance, hair loss, dry 
skin, constipation etc.) (Hadj-Kacem et al. 2009). 
Apart from physical health, patients may experience 
the ramifications of HT in their mental health and 
quality of life in general (Jonklaas & Burman, 2013) as 
they often report symptoms of chronic fatigue, 
irritability, memory or other cognitive problems (Ott et 
al. 2011). Several psychiatric co-morbidities have been 
reported (e.g. depression, anxiety, panic disorder etc.), 
although depression constitutes the capstone of these 
disorders especially in overt hypothyroidism (Kung 
1995, Matsubayashi et al. 1996, Radosavljevic et al. 
1996). The end result of these multiple health 
problems is that patients are subject to great stress.  
 Although stress has not been recognized as a 
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risk factor for HT, it is well-established that it affects 
endocrine and immune mechanisms implicated also in 
HT (Chrousos & Elenkov 2006, Mikoś 2014,  
Tsatsoulis 2006). For instance, hyperactivity of the 
hypothalamic-pituitary- adrenal axis of stress results in 
increased levels of cortisol in the bloodstream causing 
downregulation of the thyroid hormones and 
hypothyroidism (Tsigos & Chrousos 2002). Also, 
acute stress has immuno-enhancing properties favoring 
inflammation (Dhabhar 2014, Tsigos & Chrousos 
2002) which in the context of autoimmunity could 
result in clinical relapse. On the other hand, chronic 
stress is associated with many perturbations of the 
immune system, mainly with Th1 to Th2 shift, leading 
to enhanced humoral responses (Elenkov & Chrousos 
1999, Wilder 2002).  
 So far, there is scarce evidence on the role of 
stress management in HT. Patients with HT might 
benefit from interventions focusing on ameliorating 
anxiety, stress, depression and improving healthy 
lifestyle. The biopsychosocial intervention NET 
(Neuro-Emotional Technique) showed no benefits for 
thyroid function tests and physical, mental and general 
health (Brown et al. 2015). On the other hand, the 
intervention held by Moncayo and Moncayo (2014), 
which included magnesium supplementation and 
relaxation treatment, was notably beneficial leading to 
improvement of the psychological stress and the 
thyroid-related symptoms in 90% of patients with 
thyroiditis. 
 The primary aim of this two-arm randomized 
controlled study was to examine the impact of a stress 
management program on the thyroid antibodies and 
thyroid-stimulating hormone (TSH) levels of women 
with HT. Secondary endpoints included the effect on 
body mass index (BMI), lifestyle, depression, anxiety 
and stress. 
  
 
 
Materials and Methods 
 
This two-arm, parallel group, non-blind, randomized 
controlled study was conducted at the Naval Hospital 
of Athens in Greece, from November 2015 to July 
2016, after receiving approval by the Ethics and 
Education Committee of the hospital. Eligible 
participants were adult women (≥ 18 years of age) with 
Hashimoto's thyroiditis, residents of Athens and 
literate in Greek. Patients were excluded if they 
suffered a mental illness, received any medication or 
participated in any other stress management program. 
 The participants who met the inclusion criteria 
were randomized in two groups on the basis of random 
numbers generated by web-based random number 
generator to cosmic radiation (random.org). The 
participants of each group were informed about the 
purpose of the program. After obtaining written 
informed consent to participate in the study, they 
completed questionnaires for baseline measurements. 
The intervention group participated in an 8-week stress 
management program which included stress 
management and lifestyle counseling in 8 weekly 
sessions. Controls received standard care by their 
physicians. The timeline and content of the stress 
management program are presented in Table 1.  
 
Measurements  
Socio-demographic and Anthropometric 
Characteristics  
Participants’ socio-demographic characteristics i.e. 
age, education, marital and smoking status as well as 
BMI (i.e. their weight in kilograms divided by the 
square of their height in meters) were recorded upon 
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Sessions 
timeline 
Session content 
1st week 
Lifestyle and routine changes 
to healthier direction 
2nd week Diaphragmatic breathing 
3d week 
Progressive relaxation 
technique 
4th week Cognitive reconstruction 
5th week Diet adjustments 
6th week Guided imagery 
7th, 8th week 
Conversation and encourag-
ing the adoption of the tech-
niques 
Table 1. Timeline and content of the program sessions 
Figure 1. Diagram depicting the study flow chart. 
entry and at the end of the study.  
 
Levels of anti-TPO, anti-TG and TSH 
Thyroid function tests were evaluated at baseline and 
after 8 weeks. Levels of thyroid autoantibodies (anti-
TPO, anti-TG) were measured with the classic method 
of immunofluorescence and TSH was measured with 
the chemiluminescent third-generation method, as 
described elsewhere (Spencer 2013). 
 
Health Lifestyle and Personal Control Questionnaire 
(HLPCQ) 
The healthy lifestyle and personal control 
questionnaire (HLPCQ), is a psychometric tool 
consisting of 26-items, designed for and weighted in 
the Greek population (Darviri et al. 2014). 
Respondents are asked to indicate the frequency of 
some habits in their everyday life on a Likert-type 
scale (1 = never or rarely, 2 = sometimes, 3 = often 4 = 
always). Twelve questions refer to nutrition, 8 refer to 
daily time management, 2 refer to organized physical 
activity and 4 are about social support practices and 
positive thinking (eg, "cleaning" of the mind during 
sleep). Higher scores indicate healthier lifestyle. 
Separate scores can be obtained on the following 
subscales: healthy dietary choices, unhealthy dietary 
avoidance, daily routine, organized physical activity, 
social support and mental control. 
 
Depression Anxiety Stress Scale-21 (DASS-21) 
DASS-21 is a questionnaire that has three subscales: 
depression, anxiety and stress (Lovibond & Lovibond 
1995). Each subscale includes 7 items to which the 
respondent is invited to answer via a 5-point Likert-
type scale. Higher scores indicate higher stress, anxiety 
or depression. This scale has been validated in the 
Greek population (Lyrakos et al. 2009). 
 
 
Statistical analysis 
Baseline socio-demographic and outcome data are 
presented as means, standard deviations (SD), or 
frequencies within groups. Between group 
comparisons for baseline data were performed using 
Pearson's chi-square and Student's t tests for 
categorical and interval characteristics, respectively. 
There were no missing data in the dataset. 
Longitudinal changes in outcome measures from 
baseline to 8 weeks (or rate of outcome change) were 
analyzed using linear mixed-effects models with 
interaction terms for study group and time points. 
Random intercepts b0 were used for the random effect 
of each participant in the model using variance 
components structure. The models' formula was the 
following: 
Yti = b0 + b1(TIMEti) + b2(GROUPi) + b3 (GROUPi)
×(TIMEti) + b'0+ eti 
where Yti is the outcome, b0 is the intercept, b1, b2, b3, 
are the fixed coefficients, b'0 is the random coefficient 
for intercept, TIMEti is the time point (t) for each 
individual (i), GROUPi is the intervention condition 
and eti is the time specific residual of the model. The 
H0 null hypothesis of interest was b3=0. By coding 
control group and baseline time as zeros (intervention 
and follow-up time as one) b3 represents the difference 
of the average rate of outcome of the intervention 
group relative to the control group.  
 The Reliable Change Index (RCI) was 
calculated for each outcome questionnaire (Jacobson & 
Truax, 1991). An absolute RCI above 1.96 denotes 
significant difference after taking into account scores, 
score variance and questionnaire's reliability. RCI was 
calculated according to the formula: RCI = (X2-X1) ÷ 
√ (SEM12 + SEM22), where X2 and X1 are the final 
and baseline outcome values and SEM is the standard 
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Characteristic 
Intervention 
(N=30) 
Control 
(N=30) 
P value 
Age, mean ± 
SD1 
45.7 ± 11.6 46.8 ± 11.7 0.72 
Married, N (%)2 16 (53.3) 22 (73.3) 0.18 
Education2 
    0.79 
Primary, N (%) 
2 (6.7) 3 (10)   
Secondary, N 
(%) 
9 (30) 7 (23.3)   
Tertiary, N (%) 19 (63.3) 20 (66.7)   
Smoking, N 
(%)2 
6 (20) 8 (26.7) 0.76 
Table 2. Baseline socio-demographic characteristics of the 
study sample (N=60). 
Characteristic 
Intervention 
(N=30) 
Mean ± SD 
Control 
(N=30) 
Mean ± SD 
P value 
anti-TPO  
(IU/ml) 
506.2 ± 
1248.2 
352.0 ± 
525.6 0.54 
anti-TG  
(IU/ml) 
451.1 ± 
808.4 
385.1 ± 
759.5 
0.75 
TSH (IU/ml) 2.2 ± 1.5 1.9 ± 1.4 0.58 
BMI (Kg/m2) 24.4 ± 4.7 25.8 ± 5.4 0.30 
HLPCQ 66.2 ± 13.1 64.6 ± 15.2 0.65 
Stress 7.5 ± 4.2 6.9 ± 4.7 0.65 
Depression 4.4 ± 4.2 4.8 ± 5.2 0.74 
Anxiety 4.5 ± 4.2 3.0 ± 2.9 0.13 
Table 3. Baseline outcome characteristics of the study 
groups (N=60)1. 
BMI: Body Mass Index, anti-TPO: Thyroid Peroxidase An-
tibody, anti-TG: Thyroglobulin Antibody, TSH: Thyroid 
Stimulating Hormone, HLPCQ: Healthy Lifestyle and Per-
sonal Control Questionnaire, 1Student's t-test 
error measurement calculated by the formula: standard 
deviation (in time1 or 2) * √ (1-Cronbach's alpha in 
time 1 or 2). The Number Needed to Treat (NNT) for 
each questionnaire was calculated (i.e. the number of 
individuals that we need to treat in order to attain 
significant improvement in 1 subject). All analyses 
were performed using SPSS 22.0v for Windows 
(Chicago IL).  
 
Results 
 
Figure 1 shows the study flowchart. Overall, 97 
patients were approached and of these, 30 were 
excluded (19 did not meet the inclusion criteria, 11 
refused to participate). Of the 67 participants, 34 were 
randomized to the intervention group, with four drop 
outs during the intervention (one patient left Athens 
and three failed monitoring due to increased family 
responsibilities). From the control group, three patients 
discontinued due to major life events. Finally, a total 
of 60 women were analyzed (30 patients in each 
group).   
 Table 2 presents the socio-demographic 
characteristics of the study sample. Most women were 
of middle age, married, of tertiary education and non-
smokers. No statistically significant group 
comparisons were noted. Table 3 presents baseline 
measurements for all the outcomes' scores. There were 
no statistically significant differences between the 
study groups at baseline. 
 Table 4 presents the results of the mixed-
effects models for the rates of outcomes' changes 
across time. Significant interaction between group and 
time (b3 in the model equation) was recorded for anti-
TG, indicating a favorable effect of the intervention on 
these antibody titers. Patients in the intervention group 
demonstrated statistically significant beneficial 
decrements in the rate change of stress, depression and 
anxiety. The HLPCQ score was also significantly 
increased in the intervention group compared to the 
control group. Although, there was a decreasing trend 
of anti-TPO and TSH in the intervention group 
compared to controls, the differences were not 
statistically significant.  
 According to Table 5, 23.3-50.0% of patients 
had significant score changes according to the RCI 
index used for the questionnaires. Based on NNT the 
strongest effect was noted for lifestyle as assessed by 
the HLPCQ. 
 
Discussion 
 
In this randomized controlled study, an 8-week stress 
management program was implemented in women 
with HT, to assess its impact on their thyroid function 
tests, mental health and lifestyle. Overall, the study 
showed that patients in the intervention group 
decreased the anti-TG titers, their stress, anxiety and 
depression levels and adopted a healthier lifestyle. The 
latter effect was found to be the strongest among the 
study measurements based on questionnaires. So far, 
there are no similar studies which corroborate or 
contradict these results. The NET study (which 
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Outcomes 
b for group × time 
interaction1 (SE) 
P value 
anti-TPO  
(IU/ml) 
-307.4 (211.6) 0.15 
anti-TG (IU/ml) -112.4 (43.6) 0.01* 
TSH (IU/ml) -0.6 (0.3) 0.07 
BMI (Kg/m2) -0.48 (0.2) 0.06 
HLPCQ 20.2 (2.8) <0.001* 
Stress -4.0 (0.8) <0.001* 
Depression -1.9 (0.7) 0.01* 
Anxiety -1.9 (0.7) 0.01* 
Table 4. Results of the linear mixed-effects models for the 
rates of outcome change. 
BMI: Body Mass Index, anti-TPO: Thyroid Peroxidase An-
tibody, anti-TG: Thyroglobulin Antibody, TSH: Thyroid 
Stimulating Hormone, HLPCQ: Healthy Lifestyle and Per-
sonal Control Questionnaire, SE: Standard Error, b: b coef-
ficient of the linear mixed-effect model for the Rates of 
Outcome Change.  
1Reference categories: control group and baseline (both 
coded as zeros)  
*P<0.05 
Characteristic  
(Cronbachs' alpha before, after) 
Intervention N, (%) Control N, (%) NNT 
HLPCQ (0.90, 0.94) 15 (50) 0 (0) 2 
Stress (0.84, 0.83) 8 (26.7) 0 (0) 12.5 
Depression (0.88, 0.89) 7 (23.3) 3 (10) 25 
Anxiety (0.81, 0.79) 7 (23.3) 0 (0) 14.3 
Table 5. Number of individuals with beneficial significant change scores according to the Reliable Change Index and the cor-
responding Number Needed to Treat values (NNT). 
HLPCQ: Healthy Lifestyle and Personal Control Questionnaire 
resulted in no clinical benefit for the patients) used a 
different approach to stress management in relation to 
our techniques (Brown et al. 2015). The WOMED 
approach for Hashimoto disease by Moncayo and 
Moncayo (2014), showed treatment success in 90% of 
the cases, using techniques that involved acupuncture 
for stress relief only to patients with high stress levels 
and magnesium supplementation to patients with low 
serum magnesium and residual symptoms of 
hypothyroidism. Therefore, the results of our study are 
not comparable to any of the studies’ findings 
mentioned above.  
 A limitation of the study was the lack of 
objective ascertainment of compliance to the stress 
management program. Patients were asked to keep a 
diary of the techniques they performed at home. 
Although their diary records showed in general perfect 
compliance, this is still a self-report assessment. 
Secondly, HT-related symptoms, which are more 
indicative of the disease severity, were not evaluated, 
although most patients were in clinical remission. 
Finally, the study did not seek for long-term data, after 
the end of the 8-week period.  
 To our knowledge, this is the first study 
showing a reduction of anti-TG titers in women with 
HT undergoing a stress management intervention. 
Although, the observed benefits in lifestyle and 
psychological health (i.e. stress, depression, anxiety) 
could account for this finding, more targeted research 
on the subject is needed to draw such a conclusion. So 
far, there is no definite epidemiological evidence 
linking stress to HT. Presumably, stress reduction 
could lead to decreased humoral immune responses 
which are responsible for antibody production 
(Dhabhar 2014). With regards to pathophysiology, 
although the connection of stress with Grave's disease 
has been adequately evidenced, this is not the case 
with HT (Damian et al. 2016). The pathogenesis of HT 
includes both cell- (Th1 and Th17) and humoral-
mediated (anti-TPO, anti-TG) immune mechanisms, 
thus the role of stress should be complex. However, 
there is still enough room for speculation; acute stress 
might exacerbate HT, while chronic stress favoring a 
Th1 to Th2 shift might be related to increased blood 
levels of the anti-TPO and anti-TG antibodies 
(Dhabhar 2014). As such, it is reasonable to expect 
from effective stress management intervention to lower 
the levels of these antibodies in the bloodstream.   
 In conclusion, short-term stress management 
had beneficial effects on the anti-TG titers, the lifestyle 
and the psychological status of women with HT. Given 
the absence of similar studies, further research is 
warranted. The role of stress management in the 
everyday clinical practice of physicians treating 
patients with HT is still questionable. However, the 
remote possibility of causing any harm, renders stress 
management a safe personalized choice for physicians 
and patients.   
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